In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. This retrospective trial included advanced-stage, ALK-positive non-small-cell lung cancer patients who were treated with first-line alectinib in terms of ALK-tyrosine kinase inhibitors, regardless of previous chemotherapy. The co-primary end points were progression-free survival both for all patients and for the treatment-naive population. The secondary end points were overall response rate, overall survival, rate of CNS progression and safety. A total of 274 patients (n = 177 for treatment-naive patients) were enrolled in the study. The median progression-free survival was 26 and 28.8 months for all patients and the treatment-naive group, respectively. The overall response rate, CNS progression rate and 1-year overall survival ratio were 77.9, 12.4 and 77%. Alectinib is a highly effective therapy with a favorable safety profile.

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2022-0083DOI Listing

Publication Analysis

Top Keywords

first-line alectinib
12
efficacy safety
8
safety first-line
8
advanced-stage alk-positive
8
alk-positive non-small-cell
8
non-small-cell lung
8
lung cancer
8
cancer patients
8
progression-free survival
8
patients treatment-naive
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!